Brokerages Set GeoVax Labs, Inc. (NASDAQ:GOVX) Price Target at $14.20

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been given a consensus recommendation of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $14.20.

A number of research firms have recently issued reports on GOVX. D. Boral Capital restated a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research report on Friday, January 31st. Alliance Global Partners began coverage on shares of GeoVax Labs in a research note on Monday, November 11th. They set a “buy” rating and a $15.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research note on Friday, November 15th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of GeoVax Labs during the fourth quarter worth approximately $104,000. Virtu Financial LLC acquired a new stake in GeoVax Labs in the third quarter valued at approximately $97,000. Geode Capital Management LLC raised its position in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares during the period. Finally, Northern Trust Corp bought a new position in shares of GeoVax Labs in the fourth quarter valued at approximately $29,000. 6.09% of the stock is currently owned by institutional investors and hedge funds.

GeoVax Labs Trading Up 2.8 %

NASDAQ GOVX opened at $1.68 on Wednesday. The company’s fifty day moving average price is $2.08 and its two-hundred day moving average price is $2.66. GeoVax Labs has a 12 month low of $1.09 and a 12 month high of $11.18.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.